Crescent Biopharma, Inc. (LS:A41BDZ) Financings

Crescent Biopharma, Inc.

Financings

RaiseDate
Public offering of ordinary shares and pre-funded warrants
Closed: US$143.7M in the latest tranche · US$14.5 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital
Jul 30, 2026
Private placement of ordinary shares and pre-funded warrants
Announced: about US$185M · US$13.41 a share · Jefferies +5
Dealers: Jefferies, TD Cowen, Guggenheim Securities, Cantor, Wedbush & Co., Piper Sandler
Buyers: Forbion; Fairmount; Vestal Point Capital; BVF Partners; ADAR1; Balyasny Asset Management; Venrock Healthcare Capital Partners
Use of proceeds: Advance preclinical and clinical development of product candidates, working capital and general corporate purposes
Dec 4, 2025

Read by 6ix AI from the company's releases